All patients achieved stable disease or better.

Updated results from CheckMate 032.

The first biomarker-driven therapy approved for HCC.

Clinically relevant differences in demographics, biology, imaging, drug efficacy, etc.

New research undertaken amongst almost 30,000 older adults.

A modest decrease in the rate of FVC vs placebo.

Efficacy maintained in 44-week extension study.

Cardiac event rates are similar between CAD patients with prediabetes and normoglycemia.

Target-controlled infusion of remifentanil adds benefit to lidocaine.

Approval realizes a chemo-free, fixed-duration treatment option.

SOLAR-1 phase 3 data may lead to alpelisib approval.

Better survival benefit in advanced nonsquamous NSCLC, even after adjusting for confounders.

Findings from ACTLACC trial.

A randomized controlled trial.